Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

Rodrigues RCTazithromycin plus hydroxychloroquineplaceboCOVID 19 outpatientssome concern
42/42 inconclusive
    Q-PROTECT (HCQ/AZI vs PLACEBO)
          NCT04349592    		 RCThydroxychloroquine plus macrolidesplaceboCOVID 19 outpatientssome concern
    		152/152 safety concern
    • inconclusive 14 % decrease in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 45 % decrease in viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons